The filing is a routine Form 144 for a director's equity compensation-related sale. The share count is negligible (69 shares), indicating no material insider sentiment signal. Monitor for any larger insider sales or changes in insider filing patterns, but this filing alone warrants no action.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Oct 15 $165.88entry
- T+1 · 5w ago −4.39%α −3.28% · $158.60
- T+5 · 26d ago −1.77%α −0.76% · $162.94
- T+20 · 5d ago −6.64%α −4.74% · $154.86
- T+22 · todayOpen
- T+60 · in 8w Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Alex M. Azar II filed a Form 144 notice of intent to sell 69 shares of Guardant Health common stock, with an estimated aggregate market value of approximately $11,032. The shares were acquired via a restricted stock lapse on October 12, 2026, and the sale is for equity compensation-related tax purposes. The proposed sale is de minimis in size relative to the company's market cap and the insider's likely holdings, carrying minimal signaling value.
Key Facts
- Insider: Director Alex M. Azar II
- Proposed sale: 69 shares of common stock
- Estimated aggregate market value: ~$11,032
- Shares acquired via restricted stock lapse on October 12, 2026
- Broker: Charles Schwab & Co., Inc.
- Filing date: October 14, 2026
- Nature of transaction: Equity compensation-related sale (tax withholding or disposition)
Financial Impact
Approximately $11,032, trivial relative to Guardant Health's market capitalization and the director's total holdings.
Risk Factors
- Form 144 is an intent to sell; the sale may not be executed.
- No material risk to shareholders from this de minimis proposed transaction.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001921094-26-001089 |
| Document: 0001921094-26-001089-index.html | 0001921094-26-001089 |
| Document: 0001921094-26-001089.txt | 0001921094-26-001089 |
Track record
38 reports on GH
3 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +22.49% at T+60 after the May 27, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $145.04 Now $144.03 −0.70% settles Dec 16
- Nov 12, 20264d ago 3 Neutral 1/10 Entry $151.70 Now $144.03 −5.06% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $151.70 Now $144.03 −5.06% settles Dec 14
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $150.87 Now $144.03 −4.53% settles Dec 7
- Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $153.43 Now $144.03 −6.13% settles Dec 4
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $168.58 Now $144.03 −14.56% settles Dec 3
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $175.00 Now $144.03 −17.70% settles Dec 2
- Oct 21, 202626d ago Institutional Cluster Neutral 3/10 Entry $162.94 Now $144.03 −11.61% settles Nov 19
- Oct 14, 20264w ago 144 Neutral 2/10 Viewing Entry $165.88 to $154.86 Now $144.03 −13.17% ▼ −6.64% −4.74% vs SPY
- Sep 17, 20268w ago Insider Cluster Bearish 5/10 Entry $179.38 to $158.60 Now $144.03 +19.71% ▲ +11.58% +11.79% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers